AU2014273817B2 - Heteromultimers with reduced or silenced effector function - Google Patents

Heteromultimers with reduced or silenced effector function Download PDF

Info

Publication number
AU2014273817B2
AU2014273817B2 AU2014273817A AU2014273817A AU2014273817B2 AU 2014273817 B2 AU2014273817 B2 AU 2014273817B2 AU 2014273817 A AU2014273817 A AU 2014273817A AU 2014273817 A AU2014273817 A AU 2014273817A AU 2014273817 B2 AU2014273817 B2 AU 2014273817B2
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
ctg
gtg
acid modifications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014273817A
Other languages
English (en)
Other versions
AU2014273817A1 (en
Inventor
Eric Escobar-Cabrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymeworks BC Inc
Original Assignee
Zymeworks BC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks BC Inc filed Critical Zymeworks BC Inc
Publication of AU2014273817A1 publication Critical patent/AU2014273817A1/en
Application granted granted Critical
Publication of AU2014273817B2 publication Critical patent/AU2014273817B2/en
Assigned to ZYMEWORKS BC INC. reassignment ZYMEWORKS BC INC. Request to Amend Deed and Register Assignors: ZYMEWORKS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
AU2014273817A 2013-05-31 2014-05-30 Heteromultimers with reduced or silenced effector function Ceased AU2014273817B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829973P 2013-05-31 2013-05-31
US61/829,973 2013-05-31
PCT/CA2014/050507 WO2014190441A1 (en) 2013-05-31 2014-05-30 Heteromultimers with reduced or silenced effector function

Publications (2)

Publication Number Publication Date
AU2014273817A1 AU2014273817A1 (en) 2015-12-03
AU2014273817B2 true AU2014273817B2 (en) 2019-03-14

Family

ID=51987817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014273817A Ceased AU2014273817B2 (en) 2013-05-31 2014-05-30 Heteromultimers with reduced or silenced effector function

Country Status (12)

Country Link
US (1) US11098105B2 (cg-RX-API-DMAC7.html)
EP (1) EP3004174B1 (cg-RX-API-DMAC7.html)
JP (1) JP6567506B2 (cg-RX-API-DMAC7.html)
KR (1) KR102332303B1 (cg-RX-API-DMAC7.html)
CN (1) CN105849129A (cg-RX-API-DMAC7.html)
AU (1) AU2014273817B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015029788B1 (cg-RX-API-DMAC7.html)
CA (1) CA2913370C (cg-RX-API-DMAC7.html)
DK (1) DK3004174T3 (cg-RX-API-DMAC7.html)
ES (1) ES2736326T3 (cg-RX-API-DMAC7.html)
RU (1) RU2655439C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014190441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP2015528003A (ja) * 2012-07-13 2015-09-24 ザイムワークス，インコーポレイテッド 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN119120423A (zh) 2016-07-01 2024-12-13 分解治疗有限责任公司 优化的二核酸酶融合体和方法
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SG11201906200WA (en) 2017-01-06 2019-08-27 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2018147245A1 (ja) 2017-02-07 2018-08-16 第一三共株式会社 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
EP3630833A1 (en) * 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
AU2018298060B2 (en) 2017-07-03 2021-02-25 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
HRP20231280T1 (hr) 2018-03-13 2024-02-02 Zymeworks Bc Inc. Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7508368B2 (ja) 2018-03-15 2024-07-01 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
WO2019241430A2 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MX2021004231A (es) * 2018-10-23 2021-06-15 Magenta Therapeutics Inc Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos.
EP3927431A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020224154B2 (en) 2019-02-21 2025-05-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CA3130628A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CA3131391A1 (en) * 2019-02-27 2020-09-03 Angiex, Inc. Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same
AU2020263487A1 (en) 2019-04-25 2021-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
EA202193322A1 (ru) * 2019-05-30 2022-03-10 Эмджен Инк. Конструирование шарнирной области для управления димеризацией антител
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AU2021246385A1 (en) * 2020-03-30 2022-12-08 Daiichi Sankyo Company, Limited Bispecific antibody
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
CN116917316A (zh) 2020-08-26 2023-10-20 马伦戈治疗公司 与NKp30结合的抗体分子及其用途
JP2024502863A (ja) 2021-01-13 2024-01-23 ビステラ， インコーポレイテッド ヒト化補体５ａ受容体１抗体及びその使用方法
EP4320147A4 (en) 2021-04-08 2025-06-18 Marengo Therapeutics, Inc. TCR-BINDING MULTIFUNCTIONAL MOLECULES AND USES THEREOF
JP7651145B2 (ja) * 2021-04-20 2025-03-26 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション 向上した癌細胞死滅効能を有する非対称抗体
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
AU2023367781A1 (en) 2022-10-25 2025-06-05 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025064435A1 (en) * 2023-09-19 2025-03-27 Imaginab, Inc. Antigen binding constructs directed to integrin αvβ6

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
RU2390527C2 (ru) * 2002-09-27 2010-05-27 Ксенкор, Инк. АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP2009504787A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
US8637315B2 (en) 2008-05-15 2014-01-28 National Research Council Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
ES2688978T3 (es) * 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
KR20230005405A (ko) * 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
WO2012133782A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CA2830254C (en) * 2011-03-16 2019-09-10 Amgen Inc. Fc variants
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
CN103827300A (zh) * 2011-06-30 2014-05-28 中外制药株式会社 异源二聚化多肽
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN112079929A (zh) 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
US10128092B2 (en) 2013-05-31 2018-11-13 Micromass Uk Limited Compact mass spectrometer
JP2016531100A (ja) 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEZAREH M ET AL, "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1", JOURNAL OF VIROLOGY, (2001), vol. 75, no. 24, pages 12161 - 12168 *

Also Published As

Publication number Publication date
EP3004174A1 (en) 2016-04-13
RU2655439C2 (ru) 2018-05-28
WO2014190441A1 (en) 2014-12-04
HK1223376A1 (en) 2017-07-28
JP2016520598A (ja) 2016-07-14
RU2015152084A (ru) 2017-07-06
KR20160023721A (ko) 2016-03-03
US11098105B2 (en) 2021-08-24
CA2913370A1 (en) 2014-12-04
EP3004174A4 (en) 2017-01-04
US20160102135A1 (en) 2016-04-14
BR112015029788A2 (pt) 2017-09-26
CA2913370C (en) 2022-12-13
EP3004174B1 (en) 2019-04-17
AU2014273817A1 (en) 2015-12-03
BR112015029788B1 (pt) 2024-01-02
DK3004174T3 (da) 2019-07-22
CN105849129A (zh) 2016-08-10
WO2014190441A9 (en) 2015-02-05
ES2736326T3 (es) 2019-12-27
JP6567506B2 (ja) 2019-08-28
KR102332303B1 (ko) 2021-11-26

Similar Documents

Publication Publication Date Title
AU2014273817B2 (en) Heteromultimers with reduced or silenced effector function
US12060436B2 (en) Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2341060B1 (en) Molecules with extended half-lives, compositions and uses thereof
JP2021048850A (ja) 遺伝子操作された免疫グロブリン重鎖−軽鎖対およびその使用
EP4026850A1 (en) Modified antigen binding polypeptide constructs and uses thereof
US20140155581A1 (en) Methods For Making Multimeric Polypeptides
KR20130135866A (ko) Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
JP2019503172A5 (cg-RX-API-DMAC7.html)
CA3113539A1 (en) Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
JP2018502550A (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
CN116761821A (zh) 抗par-2抗体及其使用方法
TW202144423A (zh) 抗ｏｘ４０抗體及其用途
US10654944B2 (en) Cell engaging binding molecules
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
KR20250126131A (ko) 항-fgfr2b 항체 및 이의 용도
WO2019197979A1 (en) Cell engaging binding molecules
HK1223376B (en) Heteromultimers with reduced or silenced effector function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ZYMEWORKS BC INC.

Free format text: FORMER NAME(S): ZYMEWORKS INC.